Converting from Wegovy (Semaglutide) 2.4 mg to Tirzepatide
Start tirzepatide at 2.5 mg weekly and escalate monthly to 5 mg, then 7.5 mg, then 10 mg, with a target maintenance dose of 10-15 mg weekly. There is no established direct dose equivalency between semaglutide 2.4 mg and tirzepatide, so you must follow the standard FDA-approved tirzepatide titration schedule starting from the lowest dose 1.
Critical Clarification
Your question mentions "Wegovy 2.5 mg pill" - Wegovy (semaglutide) does not come as a pill; it is only available as a subcutaneous injection 2. The approved doses are 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg as prefilled pens 2. If you meant the 2.4 mg weekly injection (the standard maintenance dose), the conversion guidance below applies.
Standard Tirzepatide Titration Schedule
Follow this FDA-approved monthly escalation schedule 1:
- Week 1-4: 2.5 mg weekly
- Week 5-8: 5 mg weekly
- Week 9-12: 7.5 mg weekly
- Week 13-16: 10 mg weekly
- Week 17-20: 12.5 mg weekly (optional)
- Week 21+: 15 mg weekly (target maintenance dose)
The maintenance dose is typically 10 mg or 15 mg weekly, with 15 mg providing superior weight loss outcomes 1.
Why You Cannot Directly Convert
There is no established dose equivalency between semaglutide and tirzepatide because they have different mechanisms of action. Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist 1. Recent evidence suggests:
- Tirzepatide 10 mg may be roughly equivalent to semaglutide 2.4 mg for weight loss 3
- Tirzepatide 15 mg provides superior weight loss compared to semaglutide 2.4 mg (22.5% vs 16.9% body weight reduction) 1, 4
However, you cannot skip the titration steps even if the patient was on maximum-dose semaglutide. The gradual dose escalation is essential to minimize gastrointestinal side effects 1, 5.
Practical Implementation Strategy
Timing the Switch
- Stop semaglutide and start tirzepatide 2.5 mg one week later (on the same day of the week the patient was taking semaglutide)
- Since semaglutide has a half-life of approximately 1 week, there will be some overlap in drug exposure, which is generally well-tolerated 2
Accelerated Titration Option
Recent research suggests that in patients switching from semaglutide 1.0 mg who need better glycemic control, early escalation to tirzepatide 10 mg may be beneficial 6. In this study, patients who escalated to 10 mg (rather than stopping at 7.5 mg) achieved significant HbA1c reduction (-0.7%) within 3 months.
For patients switching from semaglutide 2.4 mg specifically:
- Consider a slightly faster titration schedule if tolerating well (e.g., 3 weeks per dose instead of 4 weeks)
- Target 10-15 mg as the maintenance dose
- Monitor closely for GI side effects during escalation
Managing Side Effects
Gastrointestinal symptoms (nausea, vomiting, diarrhea) are the most common side effects and occur more frequently during dose escalation 1, 5, 7:
- If intolerable side effects occur: Delay dose escalation by 4 weeks at the current dose 2
- Counsel patients to: Eat smaller meals, stop eating when not hungry, avoid spicy foods, and stay well-hydrated 7
- Most GI symptoms improve over time with continued use 7, 8
Tirzepatide causes more GI side effects than semaglutide, particularly at higher doses 4, 9. In head-to-head trials, approximately 50% of patients on tirzepatide 15 mg experienced GI adverse events 10.
Expected Outcomes After Switching
Patients switching from semaglutide 2.4 mg to tirzepatide can expect:
- Additional weight loss: Tirzepatide 15 mg produces approximately 5-6% more weight loss than semaglutide 2.4 mg (22.5% vs 16.9% total body weight loss) 1, 4
- Improved glycemic control: If the patient has type 2 diabetes, expect HbA1c reduction of 1.9-2.2% with tirzepatide 1
- Quality of life improvement: Studies show significant improvement in diabetes treatment-related quality of life scores within 3 months of switching 11
Monitoring Requirements
During the transition and titration period:
- Blood glucose monitoring: If the patient has type 2 diabetes, monitor glucose levels closely, especially if on insulin or sulfonylureas (may need dose reduction to prevent hypoglycemia) 2
- Renal function: Monitor in patients with renal impairment or those experiencing severe GI symptoms 2
- Heart rate: Check at regular intervals (GLP-1 RAs can increase heart rate) 2
- Weight and BMI: Assess monthly during titration
Special Considerations
Contraindications and Warnings
Do not use tirzepatide if the patient has 2:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of severe hypersensitivity to tirzepatide
Medication Interactions
- Discontinue any DPP-4 inhibitors if the patient is taking them (redundant with GLP-1 receptor agonism) 7
- Reduce insulin or sulfonylurea doses if applicable to prevent hypoglycemia 7, 8
- Tirzepatide delays gastric emptying and may affect absorption of oral medications requiring rapid onset 5
Renal Dosing
No dose adjustment is required for tirzepatide based on renal function 12. This is an advantage over some other GLP-1 receptor agonists.
Common Pitfalls to Avoid
Do not start tirzepatide at a higher dose thinking the patient is already "tolerant" from semaglutide - the mechanisms differ enough that GI side effects will still occur 1
Do not skip the 2.5 mg starting dose - this significantly increases the risk of severe nausea and vomiting leading to treatment discontinuation
Do not continue both medications simultaneously - there is no benefit and increased risk of side effects 2
Do not assume non-response to semaglutide predicts non-response to tirzepatide - rare cases show paradoxical responses where patients respond to one but not the other 13